



MHT use with grade of cancer remains unclear.

ARTICLE HISTORY

Received 3 February 2021

Accepted 23 March 2021

KEYWORDS

Colorectal cancer, survival, prognostic outlook, estrogens, progestins, menopausal hormone therapy

CONTACT Johanna Simin johanna.simin@ki.se  Department of Microbiology, Tumor and Cell Biology, Centre for Translational Microbiome Research (CTMR), Karolinska Institutet, Biomedicum, Quarter 8A, Solnavägen 9, Solna SE-171 64, Sweden

Supplemental data for this article can be accessed [here](#).

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

This is an Open Access article distributed under the terms of the Creative Commons Attribution License

(<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Despite enhanced treatment possibilities during the past few decades, colorectal cancer (CRC) remain a major health threat accounting for 9% of all cancer-related deaths globally [1–3]. In Sweden, CRC is the third most common cancer among women, and the age-standardized incidence (40/100,000 women in 2015) is unsurprisingly lower compared with men, as male sex is a risk factor for this malignancy [1,3]. Worrisomely, half of the individuals are expected to develop metastases at some time point (unfavorably to liver, lungs, and even bone marrow) [3], underscoring the demand for preventive